Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug - CNBC
Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the latter part of the year.
Search Group
Share To
Comments
About Screade
Screade® Inc. version 86373cf, copyright 2016 - 2025
Blocked Users
Customize Dark Theme
Forgot your password?
Forgot your password?
Invite your friends
Please type emails of people you want to invite, we will send them invitation email on your behalf. Separate emails with comma if you want to invite multiple friends.
Comments